Publicaciones científicas
Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial
Douglas R Adkins 1 , Jin-Ching Lin 2 , Assuntina Sacco 3 , Jessica Ley 4 , Peter Oppelt 4 , Vyacheslay Vanchenko 5 , Nataliia Komashko 5 , Chia-Jui Yen 6 , Trisha Wise-Draper 7 , Jose Lopez-Picazo Gonzalez 8 , Sinisa Radulovic 9 , Qi Shen 10 , Holger Thurm 10 , Jean-François Martini 10 , Justin Hoffman 10 , Xin Huang 10 , Bohuslav Melichar 11 , Makoto Tahara 12
Objectives: This study examined whether palbociclib and cetuximab prolonged overall survival (OS) versus placebo and cetuximab.
Materials and methods: In this double-blind, randomized, phase 2 trial (PALATINUS), patients with platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent/metastatic head and neck squamous-cell carcinoma received cetuximab and either palbociclib (arm A) or placebo (arm B).
The primary endpoint was OS; 120 patients were required to have ≥80% power to detect a hazard ratio (HR) of 0.6 (median OS of 10 months in arm A and 6 months in arm B) using a one-sided, log-rank test (P = 0.10).
Results: 125 patients were randomized (arm A: 65, arm B: 60). Median follow-up was 15.9 months (IQR, 11.3-22.7). Median OS was 9.7 months in arm A and 7.8 months in arm B (HR, 0.82; 95% CI, 0.54-1.25; P = 0.18). Median progression-free survival was 3.9 months in arm A and 4.6 months in arm B (HR, 1.00; 95% CI, 0.67-1.5; P = 0.50). The most common treatment-related adverse events in arm A were rash (39 patients, 60.9%) and neutropenia (26, 40.6%; three febrile) and in arm B was rash (32, 53.3%).
Conclusion: There was no significant difference in median OS with palbociclib and cetuximab versus placebo and cetuximab.
CITA DEL ARTÍCULO Oral Oncol. 2021 Apr;115:105192. doi: 10.1016/j.oraloncology.2021.105192. Epub 2021 Feb 8.
Nuestros autores
